Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: Diffuse erythema as a positive predictor of complete remission

JAMA Dermatology

Volumn 150, Issue 7, 2014, Pages 776-779

  Watanabe, Rei ^a   Teague, Jessica E ^a   Fisher, David C ^b   Kupper, Thomas S ^a,b   Clark, Rachael A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

CANCER REGRESSION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CLONE; DIFFUSE ERYTHEMA; DISEASE COURSE; ELECTRON THERAPY; ERYTHEMA; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATION; LETTER; MALIGNANT T CELL; MEMORY T LYMPHOCYTE; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN BIOPSY; SKIN DISEASE; T CELL DEPLETION; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ERYTHEMA; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84904106268     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.10099     Document Type: Letter

References (3)

1. Clark RA,Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):ra7.
2. Campbell JJ, Clark RA,Watanabe R, Kupper TS. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767-771.
3. Clark RA, Chong B,Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006;176(7):4431-4439. (Pubitemid 44264423)